Fulgent Genetics 3Q2026 conference call and webcast - FULGENT GENETICS INC

Financial Performance:

• Q3 2026 revenue totaled $90.4 million, an 8% YoY and 6% sequential increase, driven by the integration of Baco Diagnostics and StrataDx which contributed $21.8 million.
• Segment revenues: Precision diagnostics ($41.8M, -18% YoY), Anatomic pathology ($40.9M, +57% YoY), and Biopharma services ($7.7M, +5% YoY).
• Non-GAAP gross margin improved to 36.3% (vs. 35.3% GAAP) due to better collection rates and fixed cost leverage; GAAP operating margin improved to -24.9% (vs. -42.3% in Q2).
• Net loss narrowed to $13.2 million ($0.48/share) on a GAAP basis and $2.4 million ($0.09/share) on a non-GAAP basis, excluding equity-based compensation and amortization.
• Adjusted EBITDA loss improved to $7.5 million from $17.1 million in the prior quarter.
• Cash and equivalents increased by $100.9 million to $652.4 million, primarily driven by a $112.3 million federal tax refund; $15,000 shares repurchased in Q3, with $630 million cash projected year-end.
• Operating expenses decreased to $44.8 million (non-GAAP) from $49.2 million, aided by a $3.2 million bad debt recovery and absence of a prior quarter impairment charge.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance reaffirmed at $330–$340 million (implying 2.3%–5.4% YoY growth), with an estimated Q4 revenue of $82–$92 million.
• Updated non-GAAP loss per share guidance for 2026 to $1.65–$1.75, an improvement from the previous $2.22–$2.35 range, reflecting disciplined spending and lower operating expenses.
• Full-year non-GAAP gross margin expected in the mid-30% range; non-GAAP operating margin expected in the low negative 20% range.
• Therapeutic development investment for 2026 revised to approximately $21 million (down from previous estimates) to advance FID-007 and FID-022 trials.
• Management anticipates Q4 to be a "nice quarter" with potential to exceed the midpoint of the revenue range, though the official range allows for modest sequential growth or flatness.
• Long-term strategy focuses on operational efficiency via AI integration, revenue cycle optimization, and cross-selling across the expanded sales organization.

Business Segments and Product Lines:

• Therapeutics: FID-007 (nano-encapsulated paclitaxel) is progressing with Phase II completion and FDA engagement; Phase III preparation underway for head and neck cancer. FID-022 (nano-encapsulated SN-38) Phase I dosing escalation ongoing, with maximum tolerated dose determination expected in H1 2027.
• Laboratory Services: Successfully integrated Baco Diagnostics and StrataDx; billing and revenue cycle management (RCM) transition showing sequential improvements despite remaining delays.
• AI & Digital Pathology: AI platform analyzed 255,000 slides in Q3 (+23% QoQ); failure rate dropped to 0.01%. Four AI modules in production with a prostate cancer grading module undergoing validation (99.7% sensitivity in testing). Five additional AI applications planned for Q4 deployment.
• Innovation: Proprietary "clean chemo" platform enables toxicity reduction while maintaining efficacy for oncology combinations.

Market and Competitive Landscape:

• Revenue cycle management improvements are directly boosting gross margins and collection rates, positioning the company to return to historical norms.
• PAMA (Protecting Access to Medicare Act) impact assessed as minimal; primary CPT codes have limited exposure to anticipated reimbursement reductions.
• Market strategy involves expanding AI portfolios to enhance diagnostic consistency and pathologist productivity, creating operating leverage as volumes grow.
• Competitive positioning strengthened by the scalability of the technology platform and the integration of acquired entities to drive productivity.

Risks and Challenges:

• Ongoing delays in billing and revenue cycle management implementation, with some final customizations still required before historical collection rates are fully restored.
• Clinical development risks associated with the FID-007 and FID-022 pipelines, including regulatory approval timelines and trial outcomes.
• Potential impacts from evolving reimbursement landscapes and PAMA rule changes, though currently viewed as manageable.
• Execution risks related to the integration of Baco and StrataDx, including aligning sales teams and consolidating operations.

Management Commentary and Tone:

• Tone is confident and optimistic, highlighting "encouraging" clinical data and strong operational progress in Q3.
• Management expressed pride in the momentum of the therapeutic pipeline and the acceleration of AI solutions in the lab.
• CFO Paul Kim emphasized the "narrowing of the EPS loss" and the favorable cash forecast revision ($610M to $630M) as evidence of disciplined financial management.
• CEO Ming Hsieh underscored the strategic value of the common platform strategy for commercializing FID-007 and FID-022.

Analyst Questions and Answers:

• Billing Transition (David Westberg/Piper Sandler): Asked for quantification of progress and collection rate recovery. Management confirmed being "deep into the game" of RCM optimization, with gross margin improvements occurring faster than anticipated; further fine-tuning is ongoing but collection rates are trending positively.
• Q4 Revenue Outlook: Analyst noted implied sequential deceleration. Management clarified the range allows for upside, aiming for higher than the midpoint, citing diversified business lines and a "nice" quarter expected.
• AI & BACO Integration: Asked about P&L impact and productivity. Management stated AI drives efficiency and quality (reducing errors), with future margin improvements expected as modules scale; BACO integration is proceeding with cross-selling and operational consolidation goals.
• Cash Position: Analyst sought confirmation on the cash build. CFO confirmed the $20M increase in year-end cash forecast is due to tax refunds and lower therapeutic spend.

Other Key Points:

• Stock repurchase program active; $630 million in cash provides a strong balance sheet for future M&A or continued R&D.
• The company expects to provide 2027 guidance in the next quarter's earnings report.
• A $112.3 million federal tax refund received was partially delayed due to IRS resource constraints but significantly bolstered liquidity.
• Failed AI analysis rate is exceptionally low at 0.01%, indicating high technical reliability of the new architecture.